Skip to main content

Cellectis Redeeming Bonds for $66M

NEW YORK (GenomeWeb News) – Cellectis today announced it is redeeming all bonds issued on Nov. 3, 2011 into shares for a total of €50 million ($66 million).

The bonds were issued to FSI, or Fonds Stratégique d'Investissement, and industrialist Pierre Bastid.

The bonds are being redeemed into a total of 6.25 million shares of Cellectis stock at €8 per share. The redemption follows three consecutive trading days when Cellectis' stock exceeded €8 per share, the Paris-based gene engineering firm said.

Its board of directors is also issuing FSI and Bastid a total of 54,660 additional shares, split evenly between the two parties, of Cellectis stock at a price of €7.8392 per share, the company said.

After the redemption, Cellectis will have a total of 20.4 million outstanding shares. FSI and Bastid each hold almost 3.2 million shares, or about 15 percent of Cellectis' outstanding shares.

The Scan

Call to Look Again

More than a dozen researchers penned a letter in Science saying a previous investigation into the origin of SARS-CoV-2 did not give theories equal consideration.

Not Always Trusted

In a new poll, slightly more than half of US adults have a great deal or quite a lot of trust in the Centers for Disease Control and Prevention, the Hill reports.

Identified Decades Later

A genetic genealogy approach has identified "Christy Crystal Creek," the New York Times reports.

Science Papers Report on Splicing Enhancer, Point of Care Test for Sexual Transmitted Disease

In Science this week: a novel RNA structural element that acts as a splicing enhancer, and more.